Ublituximab-xiiy (Briumvi)

Ublituximab-xiiy is monoclonal antibody that is used to reduce the frequency of relapses and delay the accumulation of physical disability in patients with RRMS. It exerts its physiologic effects through binding to CD20 on the surface of B lymphocytes which results in antibody-dependent and complement mediated cell lysis. Ublituximab is Food and Drug administration (FDA) approved for the treatment of relapsing forms of MS to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. <a id="